Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
CONCLUSION: This modified pre-lysis procedure provides a sensitive, robust, time efficient, and relatively cost-effective alternative for MRD testing by MFC at 10-5 , facilitating clinically meaningful deeper response assessment for MM, CLL, and B-NHL. This method adaptation may facilitate more widespread adoption of highly sensitive flow cytometry-based MRD assessment.
PMID: 32530574 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Bayly E, Nguyen V, Binek A, Piggin A, Baldwin K, Westerman D, Came N Tags: Cytometry B Clin Cytom Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hodgkin's Disease | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Study